Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may unlock why some epilepsy patients stop breathing during sleep

NCT ID NCT07249034

Not yet recruiting Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses brain scans to see how epilepsy changes a brain chemical called adenosine in areas that control breathing and wakefulness. Researchers will compare 50 people with drug-resistant epilepsy to healthy volunteers. The goal is to better understand why some epilepsy patients may stop breathing during sleep, a condition linked to sudden unexpected death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could reveal why some epilepsy patients are at risk of sudden death during sleep, pointing toward future prevention strategies.
What could go wrong
This is an early observational study with only 50 participants, so findings may not apply broadly. It aims to understand mechanisms, not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT FOCAL EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy idiopathic generalized epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-RESISTANT FOCAL EPILEPSY EPILEPSY HEALTHY CONTROLS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospices Civils de Lyon

    Bron, 69500, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.